NDC 30798-856 - Dextrose
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 30798-856
- Package NDCs from labels
- 30798-856-17
- Manufacturer
- Durvet
- Effective date
- 2025-07-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Dextrose - Durvet | Durvet | 2025-07-28 | OTC ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 30798-856-17 | Dextrose | 500 mL in 1 BOTTLE, PLASTIC | INJECTION, SOLUTION | 500 | 6 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| DEXTROSE MONOHYDRATE | ACTIVE INGREDIENT | LX22YL083G | DEXTROSE INJECTION, SOLUTION [DURVET] | 4 | |
| ANHYDROUS DEXTROSE | ACTIVE MOIETY | 5SL0G7R0OK | DEXTROSE INJECTION, SOLUTION [DURVET] | 4 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lactated Ringers and Dextrose | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | Fresenius Kabi USA, LLC | 1b912c7e-f005-4af4-b683-083440964249 | 2024-05-22 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride | POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE | Fresenius Kabi USA, LLC | 55d9ae37-4553-47e7-a2e3-86b48b5227cd | 2024-05-08 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE | Fresenius Kabi USA, LLC | f0cc6713-4d47-49be-8116-901c99002b6b | 2024-05-07 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE | Fresenius Kabi USA, LLC | 97001218-086c-430a-9e0d-6c7031c91d94 | 2024-05-06 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE | Fresenius Kabi USA, LLC | fe5b5182-c859-4c74-b2e0-467be5b2e329 | 2024-05-06 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Fresenius Kabi USA, LLC | f2379398-a07b-417e-a022-f7b41f962067 | 2024-04-24 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose monohydrate | DEXTROSE MONOHYDRATE | HF Acquisition Co LLC, DBA HealthFirst | d7c4f9eb-9b89-c5a3-e053-2a95a90a28a2 | 2024-02-22 | Warnings, Adverse reactions | LX22YL083G |
| 50% DEXTROSE | 50% DEXTROSE | HF Acquisition Co LLC, DBA HealthFirst | 763b1cb8-1151-5f59-e053-2991aa0a4e01 | 2024-02-22 | Warnings, Adverse reactions | LX22YL083G |
| DEXTROSE | DEXTROSE | HF Acquisition Co LLC, DBA HealthFirst | 75c902e8-50e7-a337-e053-2991aa0a2093 | 2024-02-19 | Warnings, Adverse reactions | LX22YL083G |
| Heparin Sodium in Dextrose | HEPARIN SODIUM AND DEXTROSE | B. Braun Medical Inc. | 92a6f533-1a3d-4734-b413-d245592454e3 | 2023-07-31 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Medical Purchasing Solutions, LLC | 677a81e5-26ba-2a69-e053-2991aa0a101a | 2023-05-30 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Medical Purchasing Solutions, LLC | ada63d44-3b37-b65d-e053-2a95a90aa088 | 2023-05-03 | Warnings, Adverse reactions | LX22YL083G |
| Anticoagulant Citrate Dextrose A | ANHYDROUS CITRIC ACID, DEXTROSE MONOHYDRATE, AND TRISODIUM CITRATE DIHYDRATE | Citra Labs LLC | 5bcd261e-ebba-4ecb-af22-e5aaeb04499b | 2023-02-14 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose Monohydrate | DEXTROSE MONOHYDRATE | International Medication Systems, Limited | fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d | 2022-12-20 | Warnings, Adverse reactions | LX22YL083G |
| 25% Dextrose Infant | 25% DEXTROSE INFANT | HF Acquisition Co. LLC, DBA Health First | 73d04839-a2bb-65dd-e053-2991aa0a82ca | 2022-12-09 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 9c80dfee-8923-4d1f-85b0-98bd68b94212 | 2022-12-07 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Corporation | 50603082-bce5-49eb-9737-e04239cfb695 | 2022-12-07 | Warnings, Adverse reactions | LX22YL083G |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) SOLUTION | Fenwal, Inc. | d55cb701-9664-4931-8754-1a8cae68da06 | 2022-11-01 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE (CPDA-1) SOLUTION | Fenwal, Inc. | f9d7f1b4-7a77-44f9-8924-10b16008b49d | 2022-11-01 | LX22YL083G | |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) | Fenwal, Inc. | 4a08a9ec-46a5-4fcf-80ee-5c33f1a8b746 | 2022-11-01 | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.